실적분석 2026년 7월 31일

AbbVie ($ABBV) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat Expectations, Full-Year Guidance Trimmed Slightly

Earnings Scorecard

Revenue: $16.990 billion (+10.2% YoY, vs. $16.762 billion estimate) ✅ Beat

EPS: Adjusted $3.65 (vs. $3.61 estimate) ✅ Beat

Guidance: Lowered — full-year 2026 adjusted diluted EPS guidance revised to $13.87–$14.07 from $13.91–$14.11 (reflecting $0.14/share dilution from the ApiPhire acquisition and $0.10/share from operational outperformance)

Stock reaction: After-hours +0.13% ($257.75) — as of 07-31 20:44 KST

Positives

Double beat on revenue and earnings: Revenue of $16.990 billion (+10.2%) and adjusted EPS of $3.65 topped estimates

Immunology one-two punch: Skyrizi $5.505 billion (+24.4%), Rinvoq $2.525 billion (+24.5%)

Neuroscience acceleration: Portfolio revenue of $3.228 billion, up 20.3% YoY

AbbVie's post-Humira growth engines — Skyrizi and Rinvoq — each delivered mid-20% growth, lifting immunology revenue to $8.786 billion (+15.1%). Double-digit total-company revenue growth versus the prior year demonstrates that these two products are fully offsetting Humira's decline.

Adjusted EPS rose 22.9% YoY, beating the Street estimate even with $0.17/share in acquired R&D asset and milestone costs baked in. In neuroscience, balanced growth across Brelvi, Botox therapeutics, and migraine treatments confirmed portfolio diversification in the numbers.

Negatives

Humira erosion: Global revenue of $756 million, down 35.9% YoY

Full-year guide trimmed slightly: ApiPhire deal dilution pulled the midpoint of full-year adjusted EPS guidance down by roughly $0.04

Oncology and aesthetics soft: Oncology -1.5%; aesthetics -0.9% ex-FX

The Humira revenue decline is an expected trajectory, but the absolute scale of the contraction is large enough that the growth trajectory could wobble if Skyrizi and Rinvoq fail to keep accelerating. The company lowered full-year adjusted EPS guidance to reflect $0.14/share of dilution from the ApiPhire Therapeutics acquisition (stake value of roughly $10.9 billion), partially offset by $0.10/share of operational outperformance from the base business.

In oncology, Imbruvica weakness dragged the segment slightly lower despite Venclexta and Elahere growth. Aesthetics was up modestly on a reported basis but effectively shrank ex-FX. Deal closing and integration costs, along with potential additional R&D spending, are also factors clouding near-term earnings visibility.

What Management Said

Management framed the quarter as one highlighted by execution and pipeline progress, emphasizing that the ApiPhire acquisition will reinforce immunology leadership and drive long-term shareholder value. The slight cut to full-year adjusted EPS guidance reflects ApiPhire dilution, while the company simultaneously highlighted outperformance in the base business, signaling that underlying business momentum remains intact.

The market has already largely priced in the immunology growth story, so the simultaneous signals of an earnings beat plus acquisition dilution and a guide adjustment were read as "growth confirmed, near-term earnings bar — be cautious." Management's confidence in a very positive long-term outlook is encouraging, but actual validation hinges on the timing of the acquisition closing and continued growth in key products in the second half.

Market Reaction and Key Points Ahead

The muted after-hours move despite the beat suggests that immunology growth expectations were already baked into the stock, while the slight full-year guide cut tied to ApiPhire acted as an offsetting factor. While both revenue and adjusted EPS exceeded estimates, the magnitude of the beat was not large, and weakness in oncology and aesthetics left the print short of being an aggressive buying catalyst.

Watch whether the ApiPhire acquisition closes in Q3 and whether the EPS dilution scale matches guidance.

Monitor whether Skyrizi and Rinvoq maintain mid-20% growth and continue to offset Humira's decline pace.

Track any signals of a rebound in oncology and aesthetics, and check for additional R&D and milestone costs in the second half.